Full Press Release Details
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) --Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the ‘Emerging Therapies for Psychiatric Disorders’ panel at Citi’s 16thAnnual BioPharma Virtual Conference on Wednesday, September 8, 2021 at 10:40 a.m. ET.
The panel will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website atwww.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
About PraxisPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visitwww.praxismedicines.comand follow us onLinkedInandTwitter.